Table 2. Univariate and multivariate analysis of patientś and tumour characteristics related to DRFS in the discovery set.
| n (events) |
Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
|
Discovery cohort | |||||
| Age | 0.010 | 0.424 | |||
| ⩽45 | 30 (21) | 1 | 1 | ||
| >45 | 49 (23) | 0.46 (0.25–0.83) | 0.68 (0.26–1–75) | ||
| Menopausal status | 0.044 | 0.544 | |||
| Premenopausal | 36 (24) | 1 | 1 | ||
| Postmenopausal | 43 (20) | 0.54 (0.30–0.98) | 0.75 (0.30–1.90) | ||
| Stage | 0.127 | ||||
| IIA, IIB | 6 (5) | 1 | |||
| IIIA, IIIB, IIIC | 73 (39) | 0.48 (0.19–1.23) | |||
| Involved lymph nodes | 0.003 | 0.026 | |||
| 0 | 25 (9) | 1 | 1 | ||
| 1–3 | 31 (18) | 1.66 (0.75–3.70) | 0.213 | 1.37 (0.60–3.14) | 0.450 |
| >3 | 22 (16) | 3.98 (1.73–9.12) | 0.001 | 3.98 (1.73–9.12) | 0.014 |
| Ki-67 score | 0.192 | ||||
| ⩽14 | 15 (10) | 1 | |||
| >14 | 64 (34) | 0.62 (0.31–1.27) | |||
| Prognostic signature | 0.001 | 0.044 | |||
| Low risk | 40 (17) | 1 | 1 | ||
| High risk | 39 (27) | 2.86 (1.52–5.36) | 2.03 (1.02–4.05) | ||
Abbreviations: CI, confidence interval; HR, hazard ratio.Bold entries denote statistically significant values.